Reportlinker Adds Renal Cell Carcimona Cancer Drug Futures

NEW YORK, Oct. 19 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Renal Cell Carcimona Cancer Drug Futures

http://www.reportlinker.com/p0315761/Renal-Cell-Carcimona-Cancer-Drug-Futures.html

AN EXCEPTIONALLY COST EFFECTIVE SERVICE INCLUDING FORMATS TO MEET EVERY INFORMATION NEED

Espicom's Renal Cell Carcinoma Cancer Drug Futures includes formats to meet differing information requirement of customers. For constant vigilance and up-to-date coverage of lung cancer drug development users can access the 24/7 daily updated web service. For strategic periodic reviews we also provide quarterly-updated reports of all drugs in a convenient pdf document.

24/7 web access

Quarterly updated pdf reports

Single cost-effective price

All updates including any new drugs added during your license period

Related news

Espicom's research methodology for forecasting and including an explanation of the competitor ratio analysis scoring system

The number of renal cell carcinoma (RCC) patients....

....by value, in the US, Europe and Japan will increase by 35.7% by 2015 (from around 613,000 in 2008 to approximately 832,000 in 2015). Approximately 18% of the RCC patient population currently receives drug therapy but, by 2015, this percentage is expected to grow reflecting an increase in the number of treatment options, improvements in drug efficacy and the use of drug therapy earlier in the course of the disease.

The total RCC sales for branded products will increase substantially from almost US$2.2 billion in 2008, to almost US$6.5 billion in 2015, with a compound annual growth rate of 16.8%. Sales will be driven by the new targeted therapies which will account for sales of around US$6.1 billion in 2015,

NOW YOU CAN STAY IN TOUCH WITH THE DEVELOPMENTS WHICH MATTER

This all new web service from Espicom, Renal Cell Carcinoma Cancer Drug Futures, assesses the future prospects for market success for individual drugs. Based on independent research and proprietary analysis, each product assessed brings the prospects for a product into clear focus. Best of all, each drug is regularly reviewed ensuring that latest developments are incorporated for you to see.

WITH EACH KEY DRUG ANALYSED IN THIS SERVICE YOU CAN...

Track the drug's progress and stay abreast of developments

Understand the drug's novelty and mode of action

Evaluate the strength of the company developing/producing the drug

Review opportunities and challenges with Espicom's unique 5-point competitive assessment

Know the launch timeframe for new products or indications

Be aware of promising mid-stage development candidates

Estimate future revenues with original 5-year forecasts for launched and leading pipeline candidates

Review significant clinical trial results

STRUCTURED ANALYSIS OF KEY DRIVERS AND DAMPENERS OF SUCCESS

For each product analysed there is an extensive and standardised review of the factors which can affect its clinical and commercial performance. Those factors include…

Novelty/rationale for mechanism of action

Current status

Proof of concept/clinical data

Development risks

Company expertise

Competition within the market-place

Sales forecast (for key late-stage and launched products)

Competitor ratio analysis score

Clinical trial results

OVER 35 RCC DRUGS INCLUDED:

Because this service is continually updated, products will be added, deleted or enhanced in response to ongoing developments throughout the course of your licence. From time-to-time drug profiles may be removed from the service for essential updating.

Approved

Aldesleukin

Bevacizumab

Everolimus

Human lymphoblastoid interferon [IFN] alpha-N1

Interferon alpha-2a

Pazopanib

Sorafenib

Sunitinib malate

Temsirolimus

Vitespen

Phase III

Axitinib

Girentuximab

Naptumomab

Tivozanib

Phase II

AGS-003

AS1411

BIBF 1120

Foretinib

IMA901

Interleukin-21

L19

Linifanib

Panobinostat

Perifosine

Ramucirumab

Regorafenib

Talactoferrin alpha

Phase I/II

Dovitinib

IMP321

OncoVAX

Dicontinued/Suspended/Withdrawn

ABT-510

ABT-751

Archexin

SAR109659

IMO-2055

CLEAR, CONCISE, AND ORIGINAL ANALYSIS GIVES YOU KEY PRODUCT INSIGHTS

Espicom's Cancer Drug Futures incorporate the latest analysis from our in-house team of life scientists and statisticians across a range of cancer areas. Their research builds upon Espicom's established knowledge base of up-to-date intelligence on thousands of pharmaceutical manufacturers and research companies, backed up by a fifteen years' of archive material.

Taking all aspects of the market into account, from clinical trials, deals and alliances to company financial performance and drug sales, the analysis and forecasting that contributes to Espicom's Cancer Drug Futures is standardised across each individual launched product or drug candidate and is founded upon a diligent and thorough research process.

With Espicom's Cancer Drug Futures you can easily evaluate the prospects of the drugs of interest to you and discover its progress in each indication. Each report provides individual and highly-detailed analysis of the drug, looking at the key factors affecting its future performance in the marketplace.

BUILD YOUR OWN DRUG FUTURES LIBRARY WITH 4D RESEARCH!

4D Research is Espicom's tailored information service. Using 4D Research, customers can build their own Futures library of individual drugs of interest. Indeed, the service can include any of Espicom's leading information services. Attractive discounts are available to buyers of multiple Futures and our cost-effective distribution license means these key data can be shared with colleagues.

CANCER SECTORS COVERED IN THE DRUG FUTURE SERVICE

Breast

Lung

Colorectal

Renal Cell Carcinoma

Prostate

Blood (coming soon)

Table of Contents

OVERVIEW ..... 1

PHASE I... 3

TREMELIMUMAB .. 3

Mode of Action . 3

Current Status .. 3

Proof of Concept/Clinical Data ...... 3

Development Risks . 3

Company Expertise . 3

PHASE I/II ..... 4

DOVITINIB ...... 4

Mode of Action . 4

Current Status .. 5

Proof of Concept/Clinical Data ...... 5

Development Risks . 5

Company Expertise . 5

IMP321 .... 6

Mode of Action . 6

Current Status .. 6

Proof of Concept/Clinical Data ...... 6

Company Expertise . 7

Competition within the Market-place .... 7

Competitor Ratio Analysis .. 7

ONCOVAX ...... 8

Mode of Action . 8

Current Status .. 8

Proof of Concept/Clinical Data ...... 8

Development Risks . 9

Company Expertise . 9

Competition within the Market-place ..10

Competitor Ratio Analysis 11

Forecast .12

PHASE II ...... 13

AGS-003 13

Mode of Action ......13

Current Status 13

Proof of Concept/Clinical Data ....13

Development Risks 14

Company Expertise 14

Competition within the Market-place ..14

Competitor Ratio Analysis 14

RCC DRUG FUTURES

Clinical Trial Results ...15

AS1411 . 16

Mode of Action ......16

Current Status 17

Proof of Concept/Clinical Data ....17

Development Risks 17

Company Expertise 17

Competition within the Market-place ..18

BIBF 1120 ..... 19

Mode of Action ......19

Current Status 19

Proof of Concept/Clinical Data ....20

Development Risks 20

Company Expertise 20

Competition Within the Market-place .21

Competitor Ratio Analysis 21

Forecast .21

Clinical Trial Results ...22

FORETINIB ... 24

Mode of Action ......24

Current Status 24

Proof of Concept/Clinical Data ....24

Development Risks 25

Company Expertise 25

Competition within the Market-place ..25

Competitor Ratio Analysis....25

IMA901 . 26

Mode of Action ......26

Current Status 26

Proof of Concept/Clinical Data ....27

Development Risks 27

Company Expertise 27

Competition within the Market-place ..27

Competitor Ratio Analysis 28

INTERLEUKIN-21 29

Mode of Action ......29

Current Status 30

Proof of Concept/Clinical Data ....30

Development Risks 30

Company Expertise 31

Competition within the Market-place ..31

Competitor Ratio Analysis 31

Clinical Trial Results ...32

L19 . 34

Mode of Action ......34

Current Status 34

LINIFANIB .... 35

Mode of Action ......35

Current Status 35

Proof of Concept/Clinical Data ....35

Development Risks 36

Company Expertise 36

Competition within the Market-place ..36

Competitor Ratio Analysis 37

PANOBINOSTAT . 38

Mode of Action ......38

Current Status 39

Proof of Concept/Clinical Data ....39

Development Risks 39

Company Expertise 39

Competition Within the Market-place .39

Competitor Ratio Analysis 40

Forecast .40

Clinical Trial Results ...41

PERIFOSINE 42

Mode of Action ......42

Current Status 43

Proof of Concept/Clinical Data ....43

Development/Commercialisation Risks ....44

Company Expertise 44

Competition within the Market-place ..45

Competitor Ratio Analysis 45

Forecast .45

RAMUCIRUMAB .. 46

Mode of Action ......46

Current Status 46

Proof of Concept/Clinical Data ....46

Development Risks 46

Company Expertise 47

Competition within the Market-place ..47

Competitor Ratio Analysis 47

Forecast .48

REGORAFENIB ... 49

Mode of Action ......49

Current Status 49

Proof of Concept/Clinical Data ....49

Development Risks 50

Company Expertise 50

Competition within the Market-place ..50

Competitor Ratio Analysis 50

Clinical Trial Results ...51

TALACTOFERRIN ALPHA 52

Mode of Action ......52

Current Status 53

Proof of Concept/Clinical Data ....53

Development Risks 54

Company Expertise 54

Competition within the Market-place ..54

Competitor Ratio Analysis 55

Clinical Trial Results ...55

PHASE III .... 57

AXITINIB 57

Mode of Action ......57

Current Status 57

Proof of Concept/Clinical Data ....58

Development Risks 58

Company Expertise 59

Competition within the Market-place ..59

Competitor Ratio Analysis 60

Forecast .60

Clinical Trial Results ...62

GIRENTUXIMAB .. 64

Mode of Action ......64

Current Status 64

Proof of Concept/Clinical Data ....65

Development Risks 65

Company Expertise 65

Competition within the Market-place ..66

Competitor Ratio Analysis 66

Forecast .67

NAPTUMOMAB ESTAFENATOX .... 69

Mode of Action ......69

Current Status 70

Proof of Concept/Clinical Data ....70

Development Risks 70

Company Expertise 70

Competition within the Market-place ..70

Competitor Ratio Analysis 71

Forecast .71

TIVOZANIB ... 73

Mode of Action ......73

Current Status 73

Proof of Concept/Clinical Data ....73

Development Risks 74

Company Expertise 74

Competition within the Market-place ..75

Competitor Ratio Analysis 75

Forecast .76

APPROVED ... 77

ALDESLEUKIN .... 77

Mode of Action ......77

Current Status 78

Proof of Concept/Clinical Data ....78

Development Risks 78

Company Expertise 79

Competition within the Market-place ..79

Competitor Ratio Analysis 80

Forecast .80

BEVACIZUMAB ... 82

Mode of Action ......82

Current Status 83

Proof of Concept/Clinical Data ....85

Development Risks 88

Company Expertise 89

Competition within the Market-place ..90

Competitor Ratio Analysis 92

Forecast .92

Clinical Trial Results ...96

EVEROLIMUS ... 100

Mode of Action ....100

Current Status .....101

Proof of Concept/Clinical Data ..103

Development Risks .....104

Company Expertise .....105

Competition within the Market-place 105

Competitor Ratio Analysis .....106

Forecast ......106

Clinical Trial Results .107

HUMAN LYMPHOBLASTOID INTERFERON [IFN] ALPHA-N1 ..... 111

INTERFERON ALPHA-2A ...... 112

Mode of Action ....112

Current Status .....112

Proof of Concept/Clinical Data ..113

Development/Commercialisation Risks ..113

Company Expertise .....113

Competition within the Market-place 114

Competitor Ratio Analysis .....114

Forecast ......114

PAZOPANIB ...... 116

Mode of Action ....116

Current Status .....116

Proof of Concept/Clinical Data ..117

Development Risks .....117

Company Expertise .....118

Competition within the Market-place 118

Data Exclusivity ...119

Patent Expiry 119

Competitor Ratio Analysis .....119

Forecast ......119

Clinical Trial Results .121

SORAFENIB ...... 122

Mode of Action ....122

Current Status .....123

Proof of Concept/Clinical Data ..124

Development Risks .....125

Company Expertise .....125

Competition within the Market-place 126

Data Exclusivity ...126

Patent Expiry 126

Competitor Ratio Analysis .....127

Forecast ......127

Clinical Trial Results .130

SUNITINIB MALATE 131

Mode of Action ....131

Current Status .....132

Proof of Concept/Clinical Data ..132

Development Risks .....133

Company Expertise .....134

Competition within the Market-place 135

Data Exclusivity ...136

Patent Expiry 136

Generic Competition ...136

Competitor Ratio Analysis .....136

Forecast ......137

Clinical Trial Results .139

TEMSIROLIMUS 142

Mode of Action ....142

Current Status .....144

Proof of Concept/Clinical Data ..144

Development Risks .....145

Company Expertise .....145

Competition within the Market-place 145

Data Exclusivity ...147

Patent Expiry 147

Competitor Ratio Analysis .....147

Forecast ......147

Clinical Trial Results .149

VITESPEN .. 151

Mode of Action ....151

Current Status .....151

Proof of Concept/Clinical Data ..152

Development Risks .....152

Company Expertise .....153

Competition within the Market-place 153

Competitor Ratio Analysis .....153

Forecast ......154

ABT-510 ..... 156

Mode of Action ....156

Current Status .....156

Clinical Trial Results .156

ABT-751 ..... 157

Mode of Action ....157

Current Status .....157

ARCHEXIN . 158

Mode of Action ....158

Current Status .....158

Proof of Concept/Clinical Data ..159

Development/Commercialisation Risks ..159

Company Expertise .....159

Competition within the Market-place 159

Competitor Ratio Analysis .....159

IMO-2055 .... 160

Mode of Action ....160

Current Status .....160

Proof of Concept/Clinical Data ..160

Company Expertise .....161

Clinical Trial Results .161

SAR109659 . 162

Mode of Action ....162

Current Status .....162

Proof of Concept/Clinical Data ..162

Development Risks .....163

Company Expertise .....163

Competition within the Market-place 163

Competitor Ratio Analysis .....164

Clinical Trial Results .164

METHODOLOGY ...... 166

To order this report:

Biotechnology Industry: Renal Cell Carcimona Cancer Drug Futures

Biotechnology Business News

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

SOURCE Reportlinker